CITIUS ONCOLOGY, INC.
No SEC Form 4 filings for $CTOR in the last 30 days.
See all $CTOR insider activity →Citius Oncology (CTOR) received a Nasdaq extension until April 19, 2027, to meet the $1 minimum bid price requirement. The company must close at or above $1 for 10 consecutive days to avoid potential delisting. The extension does not impact its current listing on the Nasdaq Capital Market.
CITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 19, 2026, Citius Oncology, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted its request for an extension through April 19, 2027 (the “Extension Notice”) to evidence compliance with the $1.00 per sha
CITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 29, 2026, Citius Oncology, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, our stockholders elected the following Class II directors for a
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CTOR (CITIUS ONCOLOGY, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent CTOR coverage spans corporate actions, earnings and financial news.
The extension highlights ongoing compliance risk; failure could trigger delisting, creating downside pressure.
The extension highlights ongoing compliance risk; failure to regain the $1.00 price could trigger delisting, pressuring the stock.
Routine governance filing with no material operational change.
The earnings miss is the dominant near-term driver, while LYMPHIR institutional vial orders and payer coverage are offsetting positives that may limit downside.
The update provides fresh demand and revenue-recognition context for LYMPHIR, plus new commercial expansion and early combination-study response signals.
AlphAI scores every news story that mentions CTOR with an AI model for sentiment and relevance, and aggregates insider trades from CITIUS ONCOLOGY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Citius Oncology (CTOR) received a Nasdaq extension until April 19, 2027, to meet the $1 minimum bid price requirement. The company must close at or above $1 for 10 consecutive days to avoid potential delisting. The extension does not impact its current listing on the Nasdaq Capital Market.
1 min readCITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 19, 2026, Citius Oncology, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted its request for an extension through April 19, 2027 (the “Extension Notice”) to evidence compliance with the $1.00 per sha
2 min readCITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 29, 2026, Citius Oncology, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, our stockholders elected the following Class II directors for a
1 min readCitius Oncology (NASDAQ:CTOR) shares fell about 10% premarket after fiscal Q3 revenue missed forecasts. Revenue was $1.5M versus $12.52M consensus, with a loss of $0.34/share versus an expected $0.03/share. LYMPHIR institutional vial orders rose 31% sequentially to 926, and 44 institutions have prescribed. Cash was $16.6M at June 30, 2026.
4 min readCitius Oncology (Nasdaq: CTOR) reported fiscal Q3 2026 results for the quarter ended June 30, 2026 and updated on LYMPHIR launch. Revenues were $1.5M for the quarter and $7.1M for nine months. Cash was $16.6M. LYMPHIR orders rose, with 44 institutions ordering since launch and institutional vials up 31% sequentially to 926 in Q3.
6 min readCITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered
6 min readCITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri CRANFORD, N.J., August 12, 2026 — Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Phar
2 min readCitius Oncology (Nasdaq: CTOR) reported commercial progress for LYMPHIR (denileukin diftitox-cxdl). It said new institutional accounts ordering LYMPHIR rose 78% quarter over quarter to 42 institutions, and wholesaler vial orders increased 31% in Q2 2026. Company estimates the initial CTCL market exceeds $400 million.
4 min readCitius Oncology (Nasdaq: CTOR) said it is expanding its LYMPHIR launch team, adding 21 field commercial professionals and eight medical science liaisons, with nationwide onboarding expected by August 2026. The buildout was facilitated by May 2026 financing and executed by EVERSANA. The company cites near 100% payer coverage and expects continued order and patient adoption growth in 2H 2026.
4 min readCitius Pharmaceuticals (Nasdaq: CTXR) secured $3.8 million in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program. This funding, obtained on February 24, 2026, strengthens the company's financial flexibility. The capital is designated to support the commercial launch of LYMPHIR and advance its late-stage pipeline programs.
2 min read
